You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Express Scripts

Last Updated: March 2, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022032

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

NDA 022032 describes OMEPRAZOLE, which is a drug marketed by Actavis Labs Fl Inc, Apotex, Aurobindo Pharma Ltd, Breckenridge, Dr Reddys Labs Ltd, Glenmark Generics, Hetero Labs Ltd Iii, Impax Labs, Lannett Co Inc, Lupin Ltd, Mylan, Sandoz, Teva Pharms Usa, Xiromed, Zydus Pharms Usa Inc, Dexcel Pharma, Dr Reddys, Sun Pharm, Cumberland Pharms, Ajanta Pharma Ltd, Aurolife Pharma Llc, Guardian Drug, Par Pharm, Perrigo R And D, Sciegen Pharms Inc, Unicorn, Zydus Pharms, Spil, and P And L, and is included in forty-four NDAs. It is available from eighty-four suppliers. There are three patents protecting this drug and one Paragraph IV challenge. Additional details are available on the OMEPRAZOLE profile page.

The generic ingredient in OMEPRAZOLE is omeprazole magnesium. There are one hundred and thirty-one drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the omeprazole magnesium profile page.
Summary for 022032
Applicant:Dexcel Pharma
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 022032
Suppliers and Packaging for NDA: 022032
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
OMEPRAZOLE omeprazole TABLET, DELAYED RELEASE;ORAL 022032 NDA L. Perrigo Company 0113-0915 0113-0915-03 3 BOTTLE in 1 CARTON (0113-0915-03) > 14 TABLET, DELAYED RELEASE in 1 BOTTLE
OMEPRAZOLE omeprazole TABLET, DELAYED RELEASE;ORAL 022032 NDA L. Perrigo Company 0113-0915 0113-0915-30 2 CARTON in 1 CARTON (0113-0915-30) > 14 BLISTER PACK in 1 CARTON > 1 TABLET, DELAYED RELEASE in 1 BLISTER PACK
Paragraph IV (Patent) Challenges for 022032
Tradename Dosage Ingredient NDA Submissiondate

Profile for product number 001

Active Rx/OTC/Discontinued:OTCDosage:TABLET, DELAYED RELEASE;ORALStrength20MG
Approval Date:Dec 4, 2007TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Aug 16, 2025Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.